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 Introduction 
 Nanotechnology enables the possibility to engineer materials 
in the nanoscale range with remarkable new physical and 
chemical properties different from their bulk, which can be 
used for a broad range of applications. This huge potential has 
led to increasing growth of research and development activi-
ties all over the world and has created an entire new class of 
materials. Nanoscale metal oxides are a well-developed sub-
class of nanoparticles known for decades in colloids long 
before the current explosion of interest in nanoscience. 
 These new properties and industrial production in high 
tonnage have raised concerns about potential adverse effects 
for the environment and for human health. Aside from the 
broad industrial use of metal oxide particles for nanotechnol-
ogy, there are substantial research and development activities 
to apply nanomaterials such as zinc oxide (ZnO)  1  or super 
paramagnetic iron oxide nanoparticles (SPIONs)  2  in medicine. 
Therefore a better understanding of the mechanisms show 
how nanomaterials interact with cells, and the consequence 
is a prerequisite for their safe and successful use in any 
application. 
 The assessment of potentially adverse or off-target effects 
is currently based on phenomenological analysis of animal 
testing—a strategy that has not changed in the last 40 years.  3 
However, the number of newly developed particles is large 
and is still increasing, as are consumer expectations about 
their safety. A full assessment of the potential side effects 
according to today’s regulations would be extremely cost 
intensive and time consuming, and its relevance for human 
beings is still doubtful.  4  Therefore new concepts for more 
efﬁ cient, cost-effective, and evidence-based testing strategies 
toward mechanistical-based understanding of the nanoparticle–
biology interaction are proposed.  5 
 Despite the broad use of traditional cell-based  in vitro cell 
monocultures, it is recognized that these models lack pheno-
typic details, physiological functions, or depict the complex 
cross-talks between different cells only partly or not at all. 
There are multitudes of new co-culture or 3D cell culture 
systems (i.e., cells cultured on 3D scaffolds or co-cultures 
of various cell types) for different tissues developed during 
the last 10–15 years, combining several relevant cell types 
for the same organ into one culture system. So far, only a few 
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have been carefully validated to whole organ or  in vivo responses.  6  
The crux of any  in vitro technology is the predictive power, 
reliability, and usefulness of these model systems for regula-
tory toxicology.  7  
 The aim of this article is to present the current developments 
in complex human cell models describing recent work in 
relation to the assessment of metal oxide nanoparticles. We 
demonstrate how far advanced human  in vitro models have 
achieved general acceptance and how the relevance and accep-
tance of these models can be further improved (e.g., for metal 
oxide nanoparticles hazard assessments). 
 Metal oxide nanoparticles enable new 
applications for industrial and medical use 
 Metal oxide nanoparticles have been identiﬁ ed as the most 
widely used type of nanoparticles in consumer products.  8  
Market estimates for production have been increasing over the 
last several years, estimated to reach 1,663,168 tons by 2020.  9  
A large variety of metal oxides are known, with a vast number 
of crystallographic structures and with metallic, insulating, or 
semiconducting electrical behavior.  10  Titanium dioxide (TiO 2 ) 
and cerium dioxide (CeO 2 ) are two important representative 
metal oxide nanoparticles that are currently used in many 
products such as sunscreens, paints (TiO 2 ), energy, and fuel 
additives (CeO 2 ). Numerous research papers, reviews, book 
chapters, and patents focus on synthetic approaches to pro-
duce highly deﬁ ned metal oxide nanoparticles. Since many of 
their chemical and physical properties depend on their size or 
shape, much effort has been dedicated to pro-
duce “perfect” particles with high yields and 
develop a synthesis method that is more gener-
ally applicable to many different nanoparticle 
systems  11  ( Figure 1 ). 
 Typical approaches for the synthesis of 
nano-metal oxides include co-precipitation and 
sol-gel techniques, microemulsions, solvother-
mal methods, and chemical vapor deposition 
(CVD). All methods have their advantages 
and disadvantages; while the co-precipitation 
method is usually easy to reproduce, size con-
trol is not necessarily easy to achieve. CVD is 
capable of producing highly uniform and pure 
nano-metal oxides but requires careful initial 
set up of the experimental parameters. Non-
aqueous solution techniques are an interesting 
alternative to aqueous sol-gel processes, since 
they can provide a large degree of crystallinity 
at low temperatures and allow for controlled 
crystal growth without the use of surfactants.  12  
 With regard to nanomedicine, SPIONs 
have attracted a lot of interest for numerous 
therapeutic and diagnostic applications, such 
as magnetic resonance imaging (MRI), drug 
delivery, hyperthermia, and cell separation.  2  
SPIONs have been synthesized with different 
compositions and phases.  13  Chemical co-precipitation is an 
easy and convenient approach to synthesize iron oxides from 
aqueous solutions, and size, shape, and composition of the 
resulting particles strongly depend on the reaction conditions, 
in particular the reactants used, pH, and ionic strength of the 
media. Monodisperse magnetic nanoparticles can alternatively 
be synthesized by high-temperature thermal decomposition of 
organometallic precursors in the presence of stabilizers.  14  The 
overall process is often compared to seed-mediated growth, 
which can be explained by the classical LaMer mechanism.  15  
Although the particle size distribution can be much better 
controlled following these organic decomposition pathways, 
the ﬁ nal particles are dispersed in organic solvents and require 
a subsequent phase transfer step from the organic solvent 
into water. 
 Although signiﬁ cant progress was made in recent years to 
evaluate the toxicological proﬁ le of metal oxide nanoparticles,  16  
it is still difﬁ cult to compare these studies because of biological 
variations (e.g., choice of cells, growing conditions, sample 
preparation, time points, and assays) and material variations 
(e.g., particle size [distributions], zeta potential [an important 
indicator of the electronic charge of the nanoparticles’ surface], 
colloidal stability, type of material, batch-to-batch variations, 
and size and grafting density of surface molecules). 
 Examples of advanced 3D  in vitro models 
 In the ﬁ eld of human health, animal testing is still the most 
prevalent model used for risk assessment of newly developed 
  
 Figure 1.  Potential applications of metal oxide nanoparticles and transmission electron 
microscope micrographs of the respective nanoparticles: (a) TiO 2 in cosmetics, (b) SiO 2 in 
wood preservatives or paints, (c) iron oxide nanoparticles as contrast agents in magnetic 
resonance imaging,  70  and (d) ZnO in solar cells. 
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nanomaterials such as metal oxides. However, three main fac-
tors create a strong need for  in vitro alternatives: regulatory 
pressure to ban animal testing, pressure to reduce cost in drug 
development, and concerns with respect to the signiﬁ cance of 
animal experiments to model human health. In addition, 
reliable and cost-effective screening systems are required not 
only for basic research questions, but also for drug discovery and 
toxicity assessment. It has been recognized during the last 
few years that not only the 3D scaffold structure seems to be 
important for the differentiation of certain cells,  17  but also the 
culturing of different cells together is an important issue for 
continuous cross-talk through intercellular signaling to main-
tain homeostasis and to coordinate immune responses.  18  Both 
aspects (i.e., 3D scaffold and cell–cell interactions) cannot be 
mimicked by simple monocultures. Therefore, the overview 
of cell models given within this review will focus only on 
recent 3D tissue engineering development for (nano) toxicology 
research ( Figure 2 ). 
 Another aspect is the ongoing discussion about the use of 
primary cells versus stable cell lines.  19 , 20  Primary cultures are 
cells isolated from animal or human tissue, whereas cell lines 
are immortalized cells that can proliferate indeﬁ nitely. Both 
systems have advantages and disadvantages, and for each model, 
the reproducibility and reliability have to be considered. If cell 
cultures are used properly, they represent a sophisticated and 
reproducible system with which basic questions can be an-
swered and which may help in understanding the physiologi-
cal processes  in vivo. 
 Artifi cial human skin model accepted for regulatory 
toxicology 
 The epidermis, which is the external surface of the skin and 
the ﬁ rst line of defense, consists of a keratinized squamous 
epithelium (corniﬁ ed layer), which is supported and nourished 
by a thick underlying layer of connective tissue referred to as 
the dermis, which has many blood vessels and contains many 
sensory receptors.  21  A major function of the skin, especially 
the  stratum corneum , which is the outer most layer of the 
keratinized squamous epithelium, is to provide a protective 
barrier against the hazardous external environment. The skin 
is relatively impenetrable to lipophilic particles larger than 
600 Daltons in size (equivalent to 2–3 nm for a structural 
protein or 0.5 nm for a globular protein), whereas lipophilic 
particles smaller than this may passively penetrate the 
skin.  22  Skin can be exposed to metal oxide nanoparticles such 
as ZnO or TiO 2 present in cosmetic products such as mois-
turizers and sunscreens as an UV (ultraviolet) adsorber.  23  The 
skin is also a potential target for drug delivery via nanocarriers.  21  
Many studies have been done with simple monocultures 
using skin epithelial cell lines, such as the epidermal cell 
line A431  24  or the immortalized human keratinocyte cell line 
HaCaT,  25  both of which have been used to study the effects 
of silver,  26  TiO 2 ,  27  or SiO 2 nanoparticles,  28  to mention some 
examples. In general, it can be stated that healthy human skin 
is an efﬁ cient barrier against most nanoparticles in cosmetics 
such as ZnO or TiO 2 .  22  
 Cytotoxicity testing of chemicals and cosmetics in  in vitro 
skin models goes back to the 1980s (OECD guideline 431, 
Organization for Economic Co-operation and Development), 
and the ﬁ rst co-cultures of skin tissue composed of human 
epidermal keratinocytes and ﬁ broblasts (cells that form the 
connective tissue that makes and secretes collagen proteins) 
from the dermis, which is between the epidermis and the 
subcutaneous tissue, were described in the 1990s.  29  In 2013, 
OECD guideline 431 was adapted to a protocol that does not 
require the use of animals, and it provides an  in vitro pro-
cedure allowing for the identiﬁ cation of non-corrosive and 
corrosive substances and mixtures. Within this guideline, the 
use of reconstructed human epidermis composed of several 
epithelial cell layers, which closely mimics the histologi-
cal, morphological, biochemical, and physiological proper-
ties of the upper parts of the human skin, is recommended. 
Commercially available models such as the EpiDerm skin 
model  30  as well as the EPISKIN  31  are two examples of vali-
dated 3D models for this guideline; however, their potential 
in hazard assessment for metal oxide nanoparticles has not 
yet been described in the literature and needs to be evaluated 
more thoroughly. 
  
 Figure 2.  Examples of advanced human  in vitro models. (a) Skin: 
All layers of the epidermis are represented in the  in vitro model for 
the human skin. (b) Lung or placenta: In this transwell model, the 
translocation of endogenous and exogenous substances across 
a biological barrier can be studied. Therefore, the substance of 
interest is added to the apical chamber, and its appearance in 
the basal chamber is analyzed. (c) Liver: This 3D model consists 
of several primary cells isolated from the liver. The porous 
membrane facilitates an optimal nutrient supply from the medium 
in the basal chamber, and the nylon screens promote cell growth 
in 3D. Adapted with permission from Reference 34. 
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 Lung and liver—Two well-established  in vitro 
co-culture models for basic research 
 As already stated previously, the 3D model of human skin 
is so far the only accepted  in vitro alternative in regulatory 
toxicity. However, many other 3D culture systems have recently 
been described in the literature for toxicity testing studies. 
One example is the liver, which plays a central role in the 
metabolic homeostasis and detoxiﬁ cation of any xenobiotic, 
which is a foreign chemical substance, reaching the liver,  32  
whereas the CYP450 enzyme is responsible for the metabo-
lism of drugs and chemicals in the hepatocytes, which are the 
main cell types in the liver.  33  A recent paper described an 
effort to build a 3D human liver chip mimicking the acinus, 
the smallest functional unit of the liver, including its oxygen 
gradient;  34  however, the prediction of this liver model for 
toxicity testing purposes has not yet been described. Another 
attempt describes a 3D liver cell co-culture composed of hepa-
tocytes, hepatic stellate cells (fat-storing cells), endothelial cells 
(thin layer of cells lining the interior surface of blood vessels), 
as well as Kupffer cells (macrophages), which has been vali-
dated to assess the toxicity of some well-known liver drugs.  35  
 Although promising 3D liver models have been reported, 
only a few papers describing metal oxide effects in these 
advanced models have been found so far. The majority of the 
hazard assessment studies for nanoparticles are still performed 
in hepatocytes  35  or Kupffer cells  36  in monocultures, and further 
research is needed until a well-accepted 3D model for the liver 
has been tested and validated thoroughly. 
 Another well-described organ for which many co-cultures 
exist is the respiratory tract. Since the morphology and function 
of the respiratory tract changes completely from the upper to the 
lower airways, many cell culture models have been established 
using primary cells or cell lines to represent the area of interest 
for a certain study. Since the lung is the main portal of entry 
for aerosolized nanoparticles,  in vitro co-cultures mimicking 
the air-blood barrier with two cell types have been described in 
the literature to study the impact of nanoparticles in the lung.  37  
 Recently, a triple cell culture  in vitro model of the human 
airway wall to study the cellular interplay and the cellular 
response of epithelial cells, human blood monocytes derived 
macrophages (i.e., professional phagocytotic cells), and den-
dritic cells (i.e., professional antigen-presenting cells to 
nanoparticles has been developed (see Reference  38 for a 
review). In addition, a quadruple-culture containing epithelial 
and endothelial cells, macrophages, as well as mast cells 
(i.e., granulocytes containing histamines) has been established.  39  
Studies using such co-cultured cell systems have reported 
different reactions compared to monoculture analysis when 
the cells were exposed to nanoparticles, including TiO 2 ;  40 , 41  
however, such reactions observed from a culture containing 
two, three, or four different types of cells merely cultured in 
the same dish are not as speciﬁ c as those that would occur in 
the human body. Thus, the architecture of the  in vitro cell 
co-culture model, in regard to the speciﬁ c organ they represent, 
is essential when nanoparticles effects are studied. 
 However, all these described lung models have thus far 
failed to provide organ-level functionalities (e.g., molecular 
transport across tissue-tissue interfaces, contributions of 
vascular and air ﬂ ow) that are required for the development of 
meaningful physiological models.  42 , 43  A potential solution to 
this problem is the development of human “organs-on-chips” 
in which microscale engineering technologies are combined 
with cultured living human cells to create microﬂ uidic devices 
that recapitulate the physiological and mechanical microenvi-
ronment of whole living organs.  44  These organomimetic micro-
devices enable the study of complex human physiology in an 
organ-speciﬁ c context and, more importantly, they offer the 
potential opportunity to develop specialized  in vitro human 
disease models that could revolutionize drug development. 
 There is no closing statement about the toxicity of metal-
oxide nanoparticles, because the research in regard to cell 
culture types and nanoparticles exposure is not standardized 
yet. However, for single types of metal oxides such as ZnO  45 – 47  
or amorphous SiO 2 ,  48 , 49  the underlying mechanism is well-
elucidated (e.g., dissociation into Zn ions or only transient 
pro-inﬂ ammatory effects, respectively), whereas others such 
as TiO 2 or AlO 2 are more controversial. 
 New technologies for complex co-culture systems 
for human  in vitro placenta model 
 The placental barrier is a fascinating and multifunctional organ 
with the highest species-to-species variability in mammals,  50  
which underlines the necessity to have access to human-based 
models. In addition to the severe thalidomide-induced birth 
defects in the 1960s  51  and exposure to particulate air pollution,  52  
the development of new concepts in nanomedicine  53  requires 
a valid and predictive human placenta  in vitro model, which 
could also be a link toward reproductive toxicology.  54  To fulﬁ ll 
these requirements, the dual perfused  ex vivo human placenta 
model was developed in 1967, allowing the placental tissue to 
stay alive in order to assess the translocation rate across the 
tissue barrier of substances or particles.  55 , 56  In the meanwhile, 
classical  in vitro approaches, such as transwell systems,  57 – 60  iso-
lated plasma membrane vesicles, or placental tissue explants,  61  
all well-established alternatives to the time-consuming  ex 
vivo model, allow higher throughput. Furthermore, the use of 
microﬂ uidics technology  62  and scaffold-free self-organized 
organoid cultures  63  are anticipated to stimulate and accelerate 
the process of  in vitro model development substantially, and 
not just for the human placenta. Knowledge of metal oxide 
particles’ off-target effects at the placental barrier is still in its 
infancy; however, several research activities are ongoing  64 – 68  to 
provide more mechanistic insights in the near future. 
 Today’s technology and engineering competences combined 
with an in-depth knowledge of the physiological responses 
of a tissue or organ and the appropriate validation strategy 
will not only create the fundamentals necessary for reliable 
and predictive models to complement and reduce animal testing, 
but also help identify faster off-target effects of substances 
or particles. 
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 Relevance of advanced  in vitro models: There is 
space for improvement 
 Conventional two-dimensional (2D) cell cultures of any 
desired organ or tissue can be used as the basis for simpliﬁ ed 
biological models in order to obtain controllable and repro-
ducible data. Such a radical simpliﬁ cation compared to the 
physiological environment should also imply that the predic-
tive power is limited.  69  The change from carcinoma cell line to 
human primary cells, from monoculture to co-cultures, from 
static to perfused systems, or from 2D to 3D culture systems 
alone or in combination can help signiﬁ cantly improve the 
physiological function of the modeled tissue or organ toward 
the  in vivo -like situation. The example of the  in vitro skin 
models that have achieved acceptance as an OECD guideline 
for skin irritation assessment in 2010 underlines in an impres-
sive way that focused development and validation over years 
of such models supported by research, authorities, industry, 
and consumers can be seen as pioneering for additional human 
 in vitro models ( Figure 3 ). 
 However, as in the case of all models, the advanced human 
 in vitro models have their limitations, too. For the determina-
tion of absorption, distribution, metabolization, or excretion, 
animal models will still have their justiﬁ cation. Close collabo-
ration and strict validation of these newly developed advanced 
 in vitro versus mammalian models with well-known bench-
marking materials or substances will accelerate the further 
development and improvement of co-culture and 3D models 
toward well-accepted alternatives to pure animal testing and 
contribute signiﬁ cantly in the “fail faster process,” the iden-
tiﬁ cation of failure as early in development as possible, for 
nanoparticle-based innovations. 
 Conclusions 
 It is time to realize that a paradigm shift in the understanding 
of toxicology toward a modern evidence-based research dis-
cipline supported by advanced  in vitro models is inevitable. 
It is already recognized that  in vitro models should be able 
to depict the complexity of an organ or tissue as far as pos-
sible, while maintaining the capability for standardization, 
high throughput, and reproducibility. However, there are still 
uncertainties in our knowledge on the toxicity of metal oxides 
and other nanoparticles that could be reduced by obtaining 
more comparable and predictive data. Hence, efforts are still 
required to develop and carefully validate advanced  in vitro 
models. Faster and reliable identiﬁ cation of toxic materials by 
using emerging new technologies will accelerate safe, sustain-
able, and functional nano-applications. 
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